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a  b  s  t  r  a  c  t
Orexin,  which  is mainly  produced  by orexin-expressing  neurons  in  the  lateral  hypothalamus  (LH),  plays
an important  role  in  pain  modulation.  Both  kinds  of  orexin-1  (Ox1)  and  orexin-2  (Ox2)  receptors  have
been  found  at  high  density  in the  ventral  tegmental  area  (VTA)  and  nucleus  accumbens  (NAc).  However,
the  quantity  of  Ox1  receptors  in  the  VTA  is more  than  that in  the NAc.  Additionally,  it seems  that  the
functional  interaction  between  the  LH,  VTA and  NAc  implicates  pain  processing  and  modulation.  In this
study,  we tried  to  examine  the involvement  of Ox2  receptors  in  the  NAc  and  VTA  using tail-ﬂick  test  as
an  animal  model  of  acute  pain  following  microinjection  of effective  dose  of  carbachol  (125  nmol/0.5  l
saline)  into  the  LH.  In this  set of  experiments,  different  doses  of  TCS  OX2  29 as  an  Ox2  receptor  antagonist
were  microinjected  into  the  VTA  (1,  7 and  20 nmol/0.3  l  DMSO)  and  the  NAc (2,  10,  20 and 40  nmol/0.5  lucleus accumbens
ntinociception
at
DMSO)  5 min  prior  to  carbachol  administration.  Administration  of  TCS  OX2  29 into  the  VTA  and  NAc dose-
dependently  blocked  intra-LH  carbachol-induced  antinociception.  However,  the  inhibitory  effect  of  TCS
OX2 29 as an  Ox2  receptor  antagonist  was  more  potent  in  the  VTA  than  that  in  the  NAc.  It seems  that  VTA
orexinergic  receptors  are  more  effective  on  LH  stimulation-induced  antinociception  and  the  modulation
of  pain  descending  inhibitory  system  originated  from  the  LH  than  those  of  the same receptors  in  the
nucleus  accumbens  in rats.. Introduction
Pain is a multidimensional experience that circumscribes physi-
al sensation, affect, and cognition. Pain is deﬁned as “an unpleasant
ensory and emotional experience associated with actual or poten-
ial tissue damage,” or described in terms of such damage. Thus
ain is an experience characterized by clear physiological and psy-
hological elements [8]. The orexinergic system is most strongly
ssociated with feeding, arousal, sleep, reward, addiction, stress,
nd pain processing [2,11,25,28,29]. The orexins (also known
s hypocretin) are neuropeptide transmitters that comprise of
wo distinct peptides called orexin-A and orexin-B. These neuro-
eptides result from prepro-orexin molecule during the proteolytic
rocess [4,26]. Orexin-1 receptor (Ox1r) is selective for orexin A
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whereas Orexin-2 receptor (Ox2r) is willing for both orexins A and
B [26]. The orexin produced by orexin-expressing neurons are gen-
erally located in the posterior hypothalamus and extend to the
dorsomedial and lateral hypothalamus (LH) [23]. Both kinds of
orexin receptors (Ox1r and Ox2r) have been found at high density
in the ventral tegmental area (VTA) [19,21].
The VTA is a group of neurons existing close to the midline
on the ﬂoor of the midbrain and is the root of the dopaminergic
cell bodies of the mesocorticolimbic dopamine (DA) system which
is widely implicated in the drug and natural reward circuitry of
the brain. In the VTA, orexins stimulate both dopaminergic and
non-dopaminergic neurons via a direct postsynaptic effect. Orexin
receptor activation in the VTA could increase DA release via pro-
jecting neurons in the nucleus accumbens (NAc) [18,20]. The NAc
is a collection of neurons that forms the main part of the ventral
striatum. Some studies suggest that this area is an important neu-
ronal substrate of pain modulation [3]. It seems that the functional
interaction between the NAc and VTA implicates pain processing. In
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ithin the VTA and NAc in antinociception induced by LH orexin-
rgic neurons stimulation by the tail-ﬂick test as an animal model
f acute pain [24]. Findings in the study mentioned above suggest
hat Ox1 receptors in the VTA and NAc are involved in the intra-LH
arbachol-induced antinociception, and LH orexinergic projections
o these areas act, in part, through Ox1 receptors within the VTA
nd NAc in pain modulation. On the other hand, it has been shown
hat the distribution of orexin receptors in these areas are not the
ame, and the quantity of Ox1 receptor in the VTA is more than
hat in the NAc [27]. Hence, in this study, we tried to examine the
nvolvement of Ox2 receptors in these areas in the antinociception
nduced by chemical stimulation of the LH in rats.
. Materials and methods
.1. Animals
Seventy six adult male albino Wistar rats (Pasteur Institute,
ehran, Iran) weighing 210–280 g were used in these experiments.
he rats were kept in a vivarium maintained at a 12:12 h light/dark
ycle at room controlled temperature (23 ± 1 ◦C) with free access
o chow and tap water. Rats were habituated to their new environ-
ent and handled for a week before the experimental procedure
egan. The animals were randomly allocated to different experi-
ental groups. Each animal was used only once. All experiments
ere executed in accordance with the Guide for the Care and Use of
aboratory Animals (National Institutes of Health Publication No.
0-23, revised 1996) and were approved by the Research and Ethics
ommittee of Shahid Beheshti and Qazvin Universities of Medical
ciences.
.2. Stereotaxic surgery
Rats were anesthetized with intraperitoneal (i.p.) injection of
0% Ketamine (100 mg/kg) and 2% Xylazine (10 mg/kg). Cannu-
ae were stereotaxically (Stoelting, USA) implanted into the VTA,
Ac and the LH unilaterally. The coordinates for these regions
ere determined by the rat brain atlas [22], AP = 4.8 mm caudal to
regma, Lat = ±0.9 mm  lateral to midline, DV = 8.3 mm ventral from
he skull surface for the VTA (cannula 23-gauge, 11 mm,  guide can-
ula was 1 mm above the appropriate injection place) and for the
Ac (cannula 23-gauge, 11 mm)  was AP = 1.7 ± 0.5 mm to bregma,
at = ±1.6 mm lateral to midline, DV = 7.8 mm ventral from the skull
urface and for the LH (cannula 23-gauge, 12 mm)  was  AP = 3 mm
audal to bregma, Lat = ±1.6 mm and DV = 8.8 mm ventral from the
kull surface. The guide cannulae were secured in their places
sing two stainless steel and Jewelers’ screws anchored to the skull
ith dental acryl cement. After the cement was completely dried
nd hardened, two stainless steel stylets were used to keep the
uide cannulae from moving during recovery period. Penicillin-
 200,000 IU/ml (0.2–0.3 ml/rat, single dose, intramusclar) was
dministered immediately after surgery. Animals were individu-
lly housed and allowed to recover for a period of 5–7 days before
he experiments.
.3. Drugs
The drugs we used are: carbachol (Carbamoylcholine chloride;
ocris Bioscience, Bristol, UK) as a cholinergic agonist and which
as dissolved in physiological saline, and TCS OX2 29 (Tocris Bio-
cience, Bristol, UK); Ox2 receptor antagonist which was  dissolved
n 10% dimethyl sulfoxide (DMSO; Sigma–Aldrich, Germany). Con-
rol animals received either normal saline or 10% DMSO as vehicles.
ll drugs were freshly prepared on the day of the experiment.ptides 47 (2013) 94–98 95
2.4. Drug administration
Microinjections were performed by lowering a stainless steel
injector cannula (30-gauge needle) with a length of 1 mm longer
than the guide cannulae into the VTA or NAc and the LH. The injector
cannula was attached to a 1-l  Hamilton syringe by polyethyl-
ene tubing (PE-20), subsequently the drug solution or vehicle was
infused unilaterally over 60 s and was left for an extra 60 s. Differ-
ent doses of carbachol were administered slowly in a total volume
0.5 l/rat over a period of 60 s into the LH. TCS OX2 29 solution or
10% DMSO as a vehicle was administered over a period of 60 s in a
total volume of 0.3 and 0.5 l into the VTA and NAc, respectively.
Injection needles were left in place for an additional 60 s to facili-
tate the diffusion of the drugs, and then the stylets were reinserted
into the guide cannulae.
2.5. Tail-ﬂick test
The nociceptive threshold was  measured by the tail-ﬂick anal-
gesiometer apparatus (Harvard Apparatus, USA). Heat was  applied
in succession, 3, 5 and 7 cm from the caudal tip of the tail as a model
of acute pain. The value of each tail-ﬂick latency (TFL) time was  cal-
culated on the average of three consecutive TFL tests in each time
point. The reaction time between the onset of heat stimulus and the
movement of tail was determined by an automatic sensor as TFL.
The light source was set at an intensity that yields baseline TFL val-
ues in the range of 3–4 s (about 45% of maximal light intensity). If at
any time the animal failed to ﬂick its tail within 10 s (cut-off point),
the tail was removed from the coil in order to prevent damage to
the skin [5,6,10]. TFLs (s) are expressed either as raw data or per-
centage of maximal possible effect (%MPE) which was calculated
from the following formula:
%MPE  = Post-drug latency (s) − Baseline latency (s)
Cut-off value (s) − Baseline latency (s) × 100
2.6. Experimental design
In this study, there were three control groups including intact,
sham-operated and saline groups (n = 6 in each group) for deter-
mining the baseline TFLs, surgical manipulation and microinjection
volume effects, respectively. To evaluate the involvement of Ox2
receptors within the VTA and NAc in antinociceptive responses
induced by LH stimulation, tail-ﬂick test was performed as a model
of acute pain. In all of the above control and experimental groups,
TFLs were recorded at 5, 15, 30, 45 and 60 min  after drugs/vehicles
administrations.
2.6.1. Dose–response effects of carbachol microinjected into the
LH on the tail-ﬂick test
The dose–response effects of intra-LH administration of differ-
ent doses of carbachol have been established in our previous work
[24]. However, in this study, a dose–response relationship for car-
bachol as a LH chemical stimulation agent on tail-ﬂick test was
re-established. After intra-LH administration of different doses of
carbachol (125 and 250 nmol/0.5 l saline; n = 6 in each group),
TFLs were tested at the time set intervals. Control animals received
saline (n = 6) instead of carbachol in the LH.
2.6.2. Effects of intra-VTA administration of Ox2 receptor
antagonist, TCS OX2 29, on antinociception induced by carbachol
into the lateral hypothalamus
In order to test the role of Ox2 receptors located within the VTA
during the LH stimulation-induced antinociception, different doses
of TCS OX2 29 (1, 7 and 20 nmol/0.3 l DMSO; n = 5–6 in each group)




















































Fig. 1. Effects of unilateral microinjection of different doses of TCS OX2 29 (TCS), an
Ox2 receptor antagonist, in the ventral tegmental area (VTA) on (A) maximal possible
effect in 5, 15, 30, 45 and 60 min  after microinjection as an index of antinociception
induced by chemical stimulation of the lateral hypothalamus (LH) and (B) area under
the curves (AUCs) calculated for %MPEs shown in (A). Ox2 receptor antagonist can
signiﬁcantly decrease the intra-LH carbachol-induced antinociception in a dose-
dependent manner. Animals received TCS OX2 29 (1, 7 and 20 nmol/0.3 l DMSO)
or  10% DMSO (0.3 l) as a vehicle in the VTA, 5 min  before intra-LH administration of6 H. Azhdari-Zarmehri et 
ere unilaterally injected into the VTA, 5 min  prior to administra-
ion of effective dose of intra-LH carbachol. It was followed by the
ail-ﬂick test at the time set intervals. In the vehicle group (n = 6),
0% DMSO was microinjected into the VTA and 2 min  later animals
eceived saline instead of carbachol in the LH.
.6.3. Effects of intra-NAc administration of Ox2 receptor
ntagonist, TCS OX2 29, on antinociception induced by carbachol
nto the lateral hypothalamus
To examine the role of intra-accumbal OX2 receptors in the LH
timulation-induced antinociception, different doses of TCS OX2 29
2, 10, 20 and 40 nmol/0.5 l DMSO; n = 5–7 in each group) were
nilaterally injected into the NAc, 5 min  prior to effective dose
f intra-LH carbachol administration. In the vehicle group (n = 6),
0% DMSO was microinjected into the NAc and 2 min  later animals
eceived saline (0.5 l) in the LH.
.7. Histology
The animals were deeply anesthetized with Ketamine and
ylazine after the experiments were accomplished. Transcardial
erfusion was carried out with 0.9% saline and 10% formalin solu-
ion. The brains were removed, blocked and cut coronally in 50 m
ections through the cannulae placements. The neuroanatomical
ocations of cannulae tips were conﬁrmed using rat brain atlas [22]
Only the results from animals with correct cannulae placements
ere included in the data analysis.
.8. Statistics
The obtained data are expressed as mean ± SEM (standard
rror of mean). The mean TFLs or the mean maximal possible
ffect (%MPE) of drugs, as an analgesic index in all control groups
ere subjected to one-way and/or two-way ANOVA followed
y protected Newman–Keuls’s or Bonferroni’s test for multiple
omparisons, respectively as needed. In order to evaluate the noci-
eptive responses, area under the curve (AUC) was calculated as raw
MPE × time by linear trapezoidal method and a single value was
sed in statistical analyses. The calculated AUC values in all exper-
mental groups were subjected to one-way ANOVA followed by
rotected Newman–Keuls test for multiple comparisons. P-values
ess than 0.05 were considered to be statistically signiﬁcant.
. Results
.1. Dose–response effects of chemical stimulation of the lateral
ypothalamus by carbachol on tail-ﬂick test as an animal model
f acute pain
In this study, two-way ANOVA for repeated measures over time
ollowed by Bonferroni’s test for %MPEs conﬁrmed a signiﬁcant dif-
erence in antinociceptive responses to carbachol microinjected
nto the LH alone, compared to that of respective saline-
reated group [Treatment effect: F(2, 75) = 26.05, P < 0.0001; Time
ffect: F(4, 75) = 0.2197, P = 0.9267; Interaction: F(8, 75) = 0.3576,
 = 0.9394; data not shown]. Moreover, one-way ANOVA followed
y Dunnett multiple comparison test also showed that there are
igniﬁcant differences in mean AUC calculated values for %MPEs
F(2, 17) = 20.89, P < 0.0001] among the different doses of carbachol
nd saline control groups.
.2. Effect of intra-VTA administration of Ox2 receptor antagonist,
CS OX2 29, on LH stimulation-induced antinociception
We  examined the effect of intra-VTA administration of TCS
X2 29 as a selective Ox2r antagonist on LH stimulation-inducedcarbachol (125 nmol/rat). Each point shows the mean ± SEM for 5–6 rats. ***P < 0.001
different from the control (vehicles) group. ††P < 0.01, †††P < 0.001 different from the
respective DMSO-carbachol group.
antinociception by carbachol in order to evaluate the receptor
speciﬁc response of Ox2 receptors in the VTA. Two-way ANOVA
for repeated measures over time followed by Bonferroni’s test
for %MPEs indicated signiﬁcant differences in antinociceptive
responses to carbachol microinjected into the LH alone or when
carbachol was concurrently administrated into the LH following
different doses of intra-VTA TCS OX2 29 as compared to those of
respective saline-treated group [Treatment effect: F(5, 145) = 38.6,
P < 0.0001; Time effect: F(4, 145) = 1.032, P = 0.3927; Interaction:
F(20, 145) = 0.9356, P = 0.5435]. Furthermore, as shown in Fig. 1,
one-way ANOVA followed by Newman–Keuls multiple compar-
ison test showed that there are signiﬁcant differences in AUC
calculated values for %MPEs [F(5, 34) = 18.46, P < 0.0001] among
the experimental and control (vehicle) groups. Data gained from
these experiments showed that intra-VTA administration of TCS
OX2 29 as an Ox2r antagonist dose-dependently prevents intra-LH
carbachol-induced antinociception in rats. Also, administration of
maximal dose of TCS OX2 29 (20 nmol/rat) alone into the VTA could
not affect the baseline TFLs (%MPEs) at time set intervals and/or AUC
calculated values compared to the vehicle group (Fig. 1).
3.3. Effect of intra-accumbal administration of Ox2 receptor
antagonist, TCS OX2 29, on LH stimulation-induced
antinociception
The dose–response effects of intra-NAc administration of selec-
tive Ox2r antagonist TCS OX2 29 on the antinociceptive response
of carbachol microinjected into the LH during a 60-min period
was observed in the following experiments. Two-way ANOVA fol-
lowed by Bonferroni’s test [Treatment effect: F(6, 174) = 44.03,
P < 0.0001; Time effect F(4, 174) = 2.449, P = 0.048; Interaction F(24,
174) = 0.8744, P = 0.6364] showed that there are signiﬁcant differ-
ences in %MPE values among the experimental and control groups.
Although one-way ANOVA followed by Newman–Keuls multi-
ple comparison test [F(6, 41) = 17.44, P < 0.0001; Fig. 2] showed
H. Azhdari-Zarmehri et al. / Pe
Fig. 2. Effect of unilateral microinjection of different doses of TCS OX2 29, an Ox2
receptor antagonist, in the nucleus accumbens (NAc) on (A) maximal possible effect
in  5, 15, 30, 45 and 60 min  after microinjection as an index of antinociception induced
by  chemical stimulation of the lateral hypothalamus (LH) and (B) area under the
curves (AUCs) calculated for %MPEs shown in (A). The high doses of Ox2 receptor
antagonist can signiﬁcantly decrease the intra-LH carbachol-induced antinocicep-
tion in rats. Animals received TCS OX2 29 (2, 10, 20 and 40 nmol/0.5 l DMSO) or


































o125 nmol/rat). Each point shows the mean ± SEM for 5–7 rats. *P < 0.05, ***P < 0.001
ifferent from the control (vehicles) group. †P < 0.05, †††P < 0.001 different from the
espective DMSO-carbachol group.
hat there are signiﬁcant differences in AUC calculated values for
MPEs among the experimental and control (vehicles) groups,
ntra-accumbal administration of TCS OX2 29 only at high doses
20 and 40 nmol/rat) could signiﬁcantly reduce %MPEs in compari-
on with DMSO respective control group that received carbachol
125 nmol/rat) in the LH. Moreover, administration of maximal
ose of TCS OX2 29 (40 nmol/rat) alone into the NAc could not affect
he AUC calculated values compared to vehicle group (Fig. 2).
. Discussion
In this study we presented a detailed analysis on the antinoci-
eptive effects caused by orexin-2 receptors in the VTA and NAc.
ur results indicated that administration of different doses of
arbachol into the LH caused an antinociceptive response in the
ail-ﬂick test. Nonetheless, the major ﬁndings were (I) the involve-
ent of Ox2 receptors within the VTA and NAc in pain modulation
n the rats; (II) administration of an Ox2r antagonist (TCS OX2 29)
nto the VTA and NAc dose dependently blocked intra-LH carba-
hol induced antinociception and (III) the antinociceptive effect of
x2 receptor in the VTA was more potent than that in the NAc.
n this experiment and pertaining to our laboratory’s last research
n Ox1 receptors [24], both SB334867 and TCS OX2 29 as Ox1 and
x2 receptors antagonists, respectively, were able to reduce the
ntinociception caused by intra-LH administration of carbachol,
nd we observed this attenuation by blocking the Ox2 receptors
ithin the VTA and NAc. These responses were stronger in the
TA than those in the NAc. Stimulation of the LH using excitatory
rugs like non-speciﬁc cholinergic muscarinic agonist (carbachol)
an elicit marked antinociception [7,13–17]. Hence, we used two
oses of carbachol, and although there was no signiﬁcant difference
n the antinociceptive effect, the lower dose was chosen [24].
Multiple brain regions receive orexinergic ﬁbers input from the
H and the perifornical area [4]. Dense orexinergic innervation is
bserved in the VTA. This area has been shown to have a robustptides 47 (2013) 94–98 97
expression of Ox1 and Ox2 receptors, and orexinergic terminals
synapse onto presumed dopaminergic and GABAergic neurons [21].
Narita and colleagues strongly support the idea that the activa-
tion of orexin-containing neurons in the VTA leads to the direct
activation of mesolimbic dopamine neurons including the NAc at
the somatodendritic level [21]. Ghalandari-Shamami et al. [9] pre-
sented that the NAc plays an important role in the modulation of
pain, and the recent studies have also supported that the NAc is
involved in the antinociception induced by intra-BLA administra-
tion of cannabinoid receptor agonist in the tail-ﬂick test [9,10,12].
In addition, it has been proven that antinociception induced by
intra-VTA DiMe- C7 decreases with intra-accumbal infusions of the
mixed dopamine receptor antagonist ﬂupenthixol [1]. Thus, our
ﬁndings in this study suggest that Ox2 receptors in the VTA and
NAc are involved in the antinociception induced by LH stimula-
tion through activation of the LH orexinergic projecting neurons to
the VTA and lesser to the NAc, and in part, through mechanisms
involved in pain descending inhibitory system in these areas.
On the other hand, the distribution of orexin receptors in these
areas are not same, and the quantity of Ox1 receptors in the VTA
is more than that in the NAc [27]. It is consistent with the results
from the previous research performed on Ox1 receptors [24]; it
has been shown that SB334867 as an Ox1 receptor antagonist is
more effective in the VTA region. As mentioned before in this study,
TCS OX2 29 as an Ox2 receptor antagonist is also more effective
in the VTA in comparison with this effect in the NAc. Therefore, it
seems that VTA orexinergic receptors and orexin system in this area
are more effective in modulation of the pain descending inhibitory
system than those of the same receptors and system in the NAc.
Furthermore, we understand that Ox1 and Ox2  receptors usually
act in adverse toward each other, but regarding these ﬁndings it
seems that these two  kinds of receptors have worked together to
decrease the antinociception induced by stimulation of hypothala-
mus. While ﬁndings from this study and other studies are novel, we
cannot say with certainty how these receptors interact with each
other.
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